Journal for ImmunoTherapy of Cancer (Nov 2023)

510 ES008, a high affinity LILRB1 specific blocking antibody activates multiple immune cells to fight cancers

Rui Gao,
Chunnian Wang,
Dawei Sun,
Hongtao Lu,
Xiaofeng Niu,
Haixia Jiang,
Quan Qiu

Affiliations

Rui Gao: Elpiscience Biopharma, Ltd., Shanghai, China
Chunnian Wang: Elpiscience Biopharma, Ltd., Shanghai, China
Dawei Sun: Elpiscience Biopharma, Ltd., Shanghai, China
Hongtao Lu: Elpiscience Biopharma, Ltd., Shanghai, China
Xiaofeng Niu: Elpiscience Biopharma, Ltd., Shanghai, China
Haixia Jiang: Elpiscience Biopharma, Ltd., Shanghai, China
Quan Qiu: Elpiscience Biopharma, Ltd., Shanghai, China

DOI: https://doi.org/10.1136/jitc-2023-SITC2023.0510
Journal volume & issue: Vol. 11, no. Suppl 1

Abstract

No abstracts available.

Published in Journal for ImmunoTherapy of Cancer

ISSN: 2051-1426 (Online)
Publisher: BMJ Publishing Group
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://jitc.bmj.com

About the journal